Search results
-
Caprica Energy and Its Choices
Harris, Jared D.; Bodily, Samuel E.; Mead, Jenny; Adolphson, Donald; Carmack, Brad; Rogers, JamesCase DARDEN-QA-0765-EDecision AnalysisJane Barrow, CEO of Caprica Energy, must recommend to the board which of three potential "unconventional" natural-gas development sites in different parts of the United States the company should pursue. The case takes place in January 2011, when the "low-hanging fruit" of natural-gas production in the United States had essentially been picked. All three of the potential sites (shale, coalbed methane, and tight sands) would require hydraulic fract...Starting at €8.20
-
Fair Play at Chisholm University
Grushka-Cockayne, Yael; Harris, Jared D.; Mead, Jenny; Adams, John; Shankar, MeeraCase DARDEN-QA-0789-EDecision AnalysisChisholm University’s new athletics director must reallocate the athletics budget in its entirety, balancing legal obligations with broader educational and financial goals. A committee appointed to work on this issue had failed to reach consensus due to disagreements about how to comply with Title IX, the law mandating gender parity in all educational offerings, including athletics. The athletics director has the facts organized into an optimizat...Starting at €8.20
-
BioRecilGent (B)
Miguel A. Ariño; Rodríguez Mariscal, ManuelCase AD-381-EDecision AnalysisThe case focuses on the development of a yet-to-be-approved drug. It presents the various options open to the company developing the drug in the context of the phases that the medicine must go through to be approved.Starting at €5.74
-
BioRecilGent (A)
Miguel A. Ariño; Rodríguez Mariscal, ManuelCase AD-380Decision AnalysisEl caso presenta el desarrollo de un fármaco que todavía no está aprobado. Muestra las distintas opciones que tiene la empresa que lo desarrolla, según las diferentes fases para su aprobación.Starting at €8.20
-
BioRecilGent (B)
Miguel A. Ariño; Rodríguez Mariscal, ManuelCase AD-381Decision AnalysisEl caso presenta el desarrollo de un fármaco que todavía no está aprobado. Muestra las distintas opciones que tiene la empresa que lo desarrolla, según las diferentes fases para su aprobación.Starting at €5.74
-
BioRecilGent (A)
Miguel A. Ariño; Rodríguez Mariscal, ManuelCase AD-380-EDecision AnalysisThe case focuses on the development of a yet-to-be-approved drug. It presents the various options open to the company developing the drug in the context of the phases that the medicine must go through to be approved.Starting at €8.20